FDA Releases Guidance on Generic-Drug Development
PTSM: Pharmaceutical Technology Sourcing and Management
The agency releases guidance on controlled correspondences related to generic-drug development.
As part of the implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), FDA has released guidance that provides information on the process for submitting correspondence to the agency requesting information related to generic-drug development. The guidance also describes FDA’s process for providing communication related to such correspondence.
Included in the guidance are the definition of a controlled correspondence, guidelines for submitting a controlled correspondence, and information on requests related to inactive ingredients and Q1/Q2 formulation assessment controlled correspondence review disciplines. The guidance also includes information on communications from FDA to requestors that submit controlled correspondence.
Source: FDA
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
